ストックスクリーナーアプリを入手
149.00
8.68%
-13.57
Natera Inc (NTRA) 最新ニュース
8 Analysts Have This To Say About Natera - Benzinga
NTRA Price Target Increased as Natera Achieves Record Growth | NTRA Stock News - GuruFocus
NTRA Stock Sees Price Target Increase by Barclays to $190 | NTRA Stock News - GuruFocus
Natera Inc (NTRA) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance - GuruFocus
Natera Inc. Reports Strong Q1 2025 Financial Growth - TipRanks
Natera Inc earnings beat by $0.14, revenue topped estimates - Investing.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Natera (NTRA) Reports Strong Q1 2025 Growth and Raises Revenue Guidance - GuruFocus
Natera Q1 2025 Earnings Call Transcript - MarketBeat
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales - Yahoo Finance
Earnings call transcript: Natera Q1 2025 beats EPS forecast, stock rises - Investing.com UK
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Natera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
NTRA Reports Strong Q1 Revenue Exceeding Expectations | NTRA Stock News - GuruFocus
Natera Q1 2025 slides: 37% revenue growth drives raised guidance - Investing.com
Natera Q1 Net Loss Narrows, Revenue Rises; Increases Full Year Revenue Outlook - marketscreener.com
Natera: Q1 Earnings Snapshot - marketscreener.com
Natera Inc (NTRA) Q1 2025 Earnings: EPS of ($0.50) Beats Estimate, Revenue Surges to $501.8 Million, Exceeding Expectations - GuruFocus
Natera Reports First Quarter 2025 Financial Results - Yahoo Finance
Natera (NTRA) to Present Significant Breast Cancer Data at 2025 ESMO Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress | NTRA Stock News - GuruFocus
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress - Stock Titan
Natera Inc (NTRA) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Cathie Wood’s ARK Makes Bold Tuesday Moves with Key Stock Swaps - Wall Street Pit
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows - Stock Titan
What To Expect From Natera’s (NTRA) Q1 Earnings - Yahoo Finance
Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas - Medical Device Network
Natera (NTRA) Highlights Promising Study Results for Sarcoma Det - GuruFocus
Natera (NTRA) Highlights Promising Study Results for Sarcoma Detection | NTRA Stock News - GuruFocus
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera | NTRA Stock News - GuruFocus
Breakthrough: Largest-Ever Sarcoma Study Validates Natera's Cancer Detection Test with 93% Accuracy - Stock Titan
Learn to Evaluate (NTRA) using the Charts - news.stocktradersdaily.com
CLASS ACTION: Kessler Topaz Meltzer & Check, LLP Reminds Natera, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Losses over $250,000 to Contact the Firm - Newsfile
Notice to Shareholders of Natera, Inc. (NTRA) Regarding Dismissal of Putative Investor Class Action - TradingView
Natera to Report its First Quarter Results on May 8, 2025 - BioSpace
Natera’s chief legal officer sells $303,299 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 By Investing.com - Investing.com Canada
Natera president Solomon Moshkevich sells $335,714 in stock By Investing.com - Investing.com South Africa
Natera executive chairman sells shares for $261,449 - Investing.com Australia
Natera co-founder Sheena Jonathan sells $66,808 in stock By Investing.com - Investing.com Canada
Natera co-founder Sheena Jonathan sells $66,808 in stock - Investing.com Australia
Natera’s chief legal officer sells $303,299 in stock - Investing.com
Natera (NasdaqGS:NTRA) Unveils DEFINE-HT Trial Insights in Heart Transplantation Study - Yahoo Finance
Minimal Residual Disease Testing Market Outlook 2024-2031 | Growth Led by Myriad, Natera & Guardant - openPR.com
Revolutionary Prospera Heart Test Shows 3X Better Transplant Monitoring Than Traditional Biopsies - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction - Yahoo Finance
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Natera, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
Natera, Inc. (NTRA): One of the Best Aggressive Growth Stocks to Buy Now - Insider Monkey
Natera launches Signatera Genome assay nationwide By Investing.com - Investing.com India
1.06%
0.43%
大文字化:
|
ボリューム (24 時間):